Emapalumab (anti-IFNγ)
Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.
Supplier | Selleck Chemicals |
---|---|
Product # | A2041 |
Sku # | A2041-1mg*5 |
Pricing | 1mg*5, $777.00 |